AgeneBio
Business Services · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1340 Smith Ave Ste 200, Baltimore, Maryl...Phone Number
(410) 779-1260Website
www.agenebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About AgeneBio
AgeneBio is dedicated to discovering and developing innovative therapeutics aimed at preserving brain function for patients at risk of neurological and psychiatric conditions. Their primary focus is on a late-stage clinical program that seeks to prevent Alzheimer's dementia. The company also addresses conditions such as mild cognitive impairment due to Alzheimer's disease, autism, and schizophrenia. AgeneBio's mission is to enhance the lives of patients, their families, and society through their therapeutic advancements.Explore more
AgeneBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AgeneBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on AgeneBio recently announced quarterly report
Funding: Get notified immidiatlly once AgeneBio has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if AgeneBio is spiking on competitors!
Click to see if AgeneBio had a recent Job posting/layoffs
Product Launch: Get notified when AgeneBio launches new products
AgeneBio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at AgeneBio
Check if AgeneBio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined AgeneBio as Masked Content
Find 2 more new buyers
Compare Similar Companies to AgeneBio
Compare insights from companies similar to AgeneBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AgeneBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AgeneBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AgeneBio.
AgeneBio financials insights
Gather financial insights about AgeneBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$3.7M
2013
Other Financing Round
$1M
Other Financing Round
$1M
2014
Private Equity
$4.1M
2015
Grant
$7.5M
2019
Grant
$500K
AgeneBio Tech Stack
A closer look at the technologies used by AgeneBio
AgeneBio News & Media
AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease
BALTIMORE, April 21, 2021 /PRNewswire/ -- AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to...AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer's and Other CNS Conditions
BALTIMORE, Sept. 11, 2019 /PRNewswire/ -- Building on previous progress in the NIH Blueprint Neurotherapeutics program, AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM), a novel...AgeneBio Announces First Patient Enrollment in the Phase 3 Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease
BALTIMORE, Jan. 17, 2019 /PRNewswire/ -- AgeneBio announced today that it has enrolled its first patient in a Phase 3 clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer's Disease (MCI due...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding AgeneBio
Sign Up For FreeTo access detailed company insights
AgeneBio is dedicated to discovering and developing innovative therapeutics aimed at preserving brain function for patients at risk of neurological and psychiatric conditions. Their primary focus is on a late-stage clinical program that seeks to prevent Alzheimer's dementia. The company also addresses conditions such as mild cognitive impairment du... Read More
